The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-γ antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 2, 2005, Pages 896-901

  Sivarajah, Ahila ^a   McDonald, Michelle C ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYL SULFOXIDE; ENDOTOXIN; LIGAND; LIPOPOLYSACCHARIDE; PARECOXIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE TARGETING; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SMOOTH MUSCLE FIBER; TISSUE INJURY;

ANILIDES; ANIMALS; CARDIOTONIC AGENTS; ENDOTOXINS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; PPAR GAMMA; RATS; RATS, WISTAR;

EID: 18044389952     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.080598     Document Type: Article

References (27)

1. Baller D, Zipfel J, and Hellige G (1980) Usefulness and limitations of myocardial oxygen consumption indices. Clin Cardiol 3:212-213.
2. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, and FitzGerald GA (2003) Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Investig 112:945-955.
3. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, and Pike JW (2001) IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 98:2443-2448.
4. Bishop-Bailey D (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823-834.
5. Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A, White CW, Harken AH, and Repine JE (1989) Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 86:2516-2520.
6. Collin M, Abdelrahman M, and Thiemermann C (2004) Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 486:233-235.
7. Collin M and Thiemermann C (2003) The PPAR-gamma ligand 15-deoxydelta12,14 prostaglandin J2 reduces the liver injury in endotoxic shock. Eur J Pharmacol 476:257-258.
8. Desvergne B and Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688.
9. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science (Wash DC) 240:889-895.
10. Fu M, Zhang J, Lin YY, Zhu X, Willson TM, and Chen YE (2002) Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 294:597-601.
11. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, and Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701.
12. Ito H, Nakano A, Kinoshita M, and Matsumori A (2003) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Investig 83:1715-1721.
13. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, and Stewart-Long P (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39:701-709.
14. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650.
15. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410.
16. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, and Ma XL (2004) Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144.
17. Murphy GJ and Holder JC (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474.
18. Nachlas MM and Shnitka TK (1963) Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol 42:379-405.
19. Padi SS, Jain NK, Singh S, and Kulkarni SK (2004) Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol 491:69-76.
20. Rowland RT, Cleveland JC, Meng X, Ao L, Harken AH, and Brown JM (1996) A single endotoxin challenge induces delayed myocardial protection against infarcation. J Surg Res 63:193-198.
21. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514.
22. Thiemermann C and Wayman NS (2001) Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size. Med Sci Monit 7:787-789.
23. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, and Thiemermann C (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16:1027-1040.
24. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
25. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, et al. (1998) Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284:751-759.
26. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, et al. (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588-2594.
27. Zacharowski K, Frank S, Otto M, Chatterjee PK, Cuzzocrea S, Hafner G, Pfeilschifter J, and Thiemermann C (2000) Lipoteichoic acid induces delayed protection in the rat heart: a comparison with endotoxin. Arterioscler Thromb Vasc Biol 20:1521-1528.